News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,174 Results
Type
Article (40876)
Company Profile (267)
Press Release (680021)
Multimedia
Podcasts (80)
Webinars (17)
Section
Business (204654)
Career Advice (2022)
Deals (35532)
Drug Delivery (110)
Drug Development (81372)
Employer Resources (173)
FDA (16403)
Job Trends (14941)
News (346352)
Policy (32723)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2565)
Accelerated approval (31)
Adcomms (24)
Allergies (137)
Alliances (49575)
ALS (168)
Alzheimer's disease (1660)
Antibody-drug conjugate (ADC) (305)
Approvals (16668)
Artificial intelligence (503)
Autoimmune disease (148)
Automation (37)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (187)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (55)
Breast cancer (632)
Cancer (4754)
Cardiovascular disease (395)
Career advice (1707)
Career pathing (35)
CAR-T (277)
CDC (44)
Celiac Disease (2)
Cell therapy (731)
Cervical cancer (36)
Clinical research (69496)
Collaboration (1670)
Company closure (4)
Compensation (1147)
Complete response letters (52)
COVID-19 (2708)
CRISPR (87)
C-suite (816)
Cystic fibrosis (143)
Data (6160)
Decentralized trials (2)
Denatured (25)
Depression (130)
Diabetes (497)
Diagnostics (6670)
Digital health (44)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (242)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (228)
Earnings (90041)
Editorial (55)
Employer branding (21)
Employer resources (151)
Events (117189)
Executive appointments (959)
FDA (19486)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1445)
Gene editing (192)
Generative AI (42)
Gene therapy (587)
GLP-1 (962)
Government (4652)
Grass and pollen (6)
Guidances (383)
Healthcare (18868)
HIV (55)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (244)
Immuno-oncology (54)
Indications (104)
Infectious disease (2967)
Inflammatory bowel disease (187)
Inflation Reduction Act (14)
Influenza (110)
Intellectual property (242)
Interviews (315)
IPO (16639)
IRA (49)
Job creations (3641)
Job search strategy (1427)
JPM (56)
Kidney cancer (15)
Labor market (83)
Layoffs (545)
Leadership (30)
Legal (7948)
Liver cancer (91)
Longevity (14)
Lung cancer (641)
Lymphoma (372)
Machine learning (42)
Management (59)
Manufacturing (777)
MASH (161)
Medical device (13755)
Medtech (13807)
Mergers & acquisitions (19953)
Metabolic disorders (1254)
Multiple sclerosis (160)
NASH (16)
Neurodegenerative disease (309)
Neuropsychiatric disorders (86)
Neuroscience (2873)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4509)
Now hiring (65)
Obesity (588)
Opinion (257)
Ovarian cancer (164)
Pain (197)
Pancreatic cancer (222)
Parkinson's disease (279)
Partnered (33)
Patents (488)
Patient recruitment (473)
Peanut (55)
People (58814)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21666)
Phase 2 (30587)
Phase 3 (22791)
Pipeline (5114)
Policy (278)
Postmarket research (2564)
Preclinical (9190)
Press Release (64)
Prostate cancer (234)
Psychedelics (47)
Radiopharmaceuticals (277)
Rare diseases (818)
Real estate (5954)
Recruiting (69)
Regulatory (24425)
Reports (51)
Research institute (2383)
Resumes & cover letters (351)
Rett syndrome (27)
RNA editing (16)
RSV (76)
Schizophrenia (146)
Series A (237)
Series B (185)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3612)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (53)
Vaccines (984)
Venture capital (86)
Weight loss (377)
Women's health (87)
Worklife (18)
Date
Today (93)
Last 7 days (565)
Last 30 days (2032)
Last 365 days (29815)
2026 (2904)
2025 (30172)
2024 (35215)
2023 (40075)
2022 (51174)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (83)
Alaska (7)
Arizona (305)
Arkansas (13)
Asia (39192)
Australia (6405)
California (11166)
Canada (3255)
China (1087)
Colorado (472)
Connecticut (470)
Delaware (332)
Europe (84430)
Florida (1662)
Georgia (353)
Hawaii (3)
Idaho (61)
Illinois (852)
India (62)
Indiana (515)
Iowa (22)
Japan (420)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1370)
Massachusetts (8001)
Michigan (319)
Minnesota (622)
Mississippi (5)
Missouri (127)
Montana (31)
Nebraska (28)
Nevada (121)
New Hampshire (78)
New Jersey (2969)
New Mexico (28)
New York (2944)
North Carolina (1436)
North Dakota (8)
Northern California (5442)
Ohio (329)
Oklahoma (21)
Oregon (41)
Pennsylvania (2257)
Puerto Rico (22)
Rhode Island (47)
South America (1107)
South Carolina (65)
South Dakota (1)
Southern California (4346)
Tennessee (172)
Texas (1724)
United States (39590)
Utah (333)
Vermont (1)
Virginia (256)
Washington D.C. (81)
Washington State (913)
West Virginia (4)
Wisconsin (106)
Wyoming (2)
721,174 Results for "evommune inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IPO
Evommune Joins IPO Class With Planned $160M Raise for Immuno Pipeline
With the shutdown ongoing, Evommune plans to close its IPO on Nov. 5 via a Securities Act clause that allows registrations to come into effect after a certain window has passed.
October 31, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Evommune Announces Commencement of Initial Public Offering
October 30, 2025
·
3 min read
Press Releases
Evommune Announces Pricing of its Initial Public Offering
November 6, 2025
·
3 min read
Press Releases
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
December 12, 2025
·
9 min read
Press Releases
Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
November 10, 2025
·
2 min read
Press Releases
Evommune to Participate in Three Upcoming September 2025 Investor Conferences
August 29, 2025
·
1 min read
Press Releases
Evommune Presents Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria During Late-Breaker at EADV 2025 Congress
September 22, 2025
·
5 min read
Press Releases
Evommune Initiates Phase 2b Trial of its Oral MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Atopic Dermatitis
August 28, 2025
·
5 min read
Press Releases
Evommune Announces Late-Breaker Presentation of Phase 2 Data for EVO756 in Chronic Inducible Urticaria at Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
September 3, 2025
·
2 min read
Business
Evommune Secures Exclusive Rights to Develop and Commercialize a Phase 2-ready IL-18 targeted fusion protein from AprilBio
Evommune, Inc. today announced it has entered into a definitive, worldwide license agreement with AprilBio Co., Ltd. (Kosdaq: 397030), a biopharmaceutical company based in South Korea dedicated to developing specialized biologics and antibody drugs, for an IL-18 targeted fusion protein.
June 24, 2024
·
3 min read
1 of 72,118
Next
